Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Interest builds in a new synthetic lethality story
Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
